High lactate concentration in tumors is associated with bad prognosis. Lactate is released by glycolytic cells in tumors and re-captured by oxidative cancer cells to feed the TCA cycle after conversion into pyruvate. Monocarboxylate transporters (MCT) mediate these fluxes of protonlinked lactate and represent attractive targets to interrupt lactate shuttle and to inhibit tumor growth.
ABSTRACT.
High lactate concentration in tumors is associated with bad prognosis. Lactate is released by glycolytic cells in tumors and re-captured by oxidative cancer cells to feed the TCA cycle after conversion into pyruvate. Monocarboxylate transporters (MCT) mediate these fluxes of protonlinked lactate and represent attractive targets to interrupt lactate shuttle and to inhibit tumor growth.
Here, we investigated the properties of 7-amino carboxycoumarins (7ACC) developed to selectively interfere with lactate fluxes in the lactate-rich tumor microenvironment. The pharmacological properties of two compounds of this family, including their effects on lactate influx and efflux and anti-tumor activity, were investigated using human cancer cell lines and mouse xenograft models. Contrary to the reference MCT1 inhibitor AR-C155858, 7ACC unexpectedly inhibited lactate influx but not efflux in tumor cells expressing MCT1 and MCT4 transporters. 7ACC delayed the growth of cervix SiHa tumors, colorectal HCT116 tumors and orthoptopic MCF7 breast tumors. MCT target engagement was confirmed by the lack of activity of 7ACC on bladder UM-UC-3 carcinoma that do not express functional MCT. 7ACC also inhibited SiHa tumor relapse post-treatment with cisplatin. Finally, we found that contrary to AR-C155858, 7ACC did not prevent the cell entry of the substrate-mimetic drug 3-bromopyruvate through MCT1, and contributed to the inhibition of tumor relapse post-3BP treatment.
In conclusion, our results indicate that 7ACC selectively affect a single part of the MCT symporter translocation cycle leading to strict inhibition of lactate influx. This singular activity is associated with antitumor effects less prone to resistance and side effects.
The monocarboxylate transporter (MCT) family (also solute carriers SLC16) actually comprises 14 members, out of which four are proton-linked short chain monocarboxylate transporters (MCT1-4) (23, 24) . In cancer, MCT1 (SLC16A1) and MCT4 (SLC16A3) are the most often described (25) . MCT1 is the most ubiquitous monocarboxylate transporter and its expression is increased in p53-deficient tumors (12) while MCT4 expression is upregulated under hypoxic conditions (26) . These two MCT also differ by their substrate affinity: MCT1
shows a greater affinity for L-lactate (Km 3-6 mM) and pyruvate (Km 1-2.5 mM) than MCT4
(with Km equal to 25-30 mM and 150 mM, respectively) (23) . Such differences are consistent with their respective metabolic roles: the high affinity of MCT1 for lactate allows this transporter to take up lactate more easily than MCT4. Also, the low affinity of MCT4 for pyruvate prevents its release from (hypoxic) glycolytic cells and thereby facilitates the cytosolic lactate conversion required to regenerate NADH from NAD + (27, 28) . As mentioned above, the actors regulating lactate shuttle in tumors are thus MCT4 for lactate release from hypoxic tumor cells and tumor-associated fibroblasts, and MCT1 for lactate uptake by oxidative tumor cells and angiogenic endothelial cells (11, 12, (15) (16) (17) .
For several decades, the only MCT inhibitors described like α-cyano-4-hydroxycinnamate (CHC) (29, 30) , organomercurials (31) and stilbene disulfonates (32, 33) suffered from a lack of selectivity (34, 35) . More recently, a new class of high affinity MCT1/MCT2 inhibitors such as AR-C155858 was developed by Astra-Zeneca (36, 37) . From our own drug discovery program, we have recently identified 7-alkylamino 3-carboxycoumarins (7ACC) as a new family of lactate flux inhibitors (synthesis and chemistry described in reference 38); the most active compound 7ACC2 (see structure in Supplementary Figure 1 ) exhibited a low IC50 of 11 nM when evaluating 14 C-lactate flux inhibition. The lack of toxicity of 7ACC in cells using glucose (instead of lactate) as a preferential energy fuel together with the lack of anticoagulant activity of these non-4-hydroxy-substituted coumarin 5 derivatives and a good ADME profile (38) supports the potential of this new family of compounds to act as anticancer drugs through inhibition of lactate flux.
In the current study, we examined how 7ACC compounds could interfere with lactate influx and efflux in a variety of cancer cells expressing MCT1 or MCT4 or both, and whether this could translate in vivo in the inhibition of different human tumor xenograft models. We also studied the capacity of 7ACC to delay tumor relapse when combined with conventional chemotherapy but also with 3-bromopyruvate, a substrate-mimetic antitumor drug known to block glycolysis (39) and to enter cells through MCT1 (40) . analyzer (Aurora Borealis).
MATERIALS AND METHODS

Cell
Immunostaining and immunoblotting. Tumors were cryosliced and sections were probed with a rat monoclonal antibody against CD31 (BD PharMingen, Lexington, KY, USA) or rabbit polyclonal antibodies against MCT1 and MCT4 followed by a secondary antibody coupled to Alexa Fluorophores as previously described (12, 15 
RESULTS.
7ACC compounds inhibit the influx but not the efflux of lactate in cancer cells.
We recently reported the chemical synthesis of new MCT inhibitors (38) (see also Suppl. Figure 1 for structures). To get further insights on the profile of lactate flux inhibition by these compounds (named 7ACC1 and 7ACC2 in the current study), we examined the capacity of these molecules to interfere with lactate uptake and lactate efflux in different human tumor cell lines. Leukemia cells are indeed reported to be highly glycolytic and to release lactate in the presence of oxygen (42) whereas oxidative cervix cancer cells have the capacity to take up lactate to fuel TCA cycle after reconversion into pyruvate (11) . As a reference compound, we used the recently developed MCT1/MCT2 inhibitor AR-C155858 (see Suppl. Fig. 1 for structure). We found that in cervix cancer SiHa cells which express both MCT1 and MCT4 ( Figure 1A ), the 7ACC compounds blocked lactate influx whereas the AR-C155858 compound failed to do so ( Figure 1B) ; similar results were obtained with another cervix cancer cell line (Hela) (not shown) but also with human pharynx squamous carcinoma FaDu cells (Suppl. Figure 2 ). By contrast, we observed that lactate efflux by the highly glycolytic leukemia cells HL60 which express MCT1 but not MCT4 ( Figure 1A In a second set of experiments, we examined the possibility to combine MCT inhibitors and 3-bromopyruvate (3BP). This compound was indeed recently reported to enter cells through MCT1 (40), a process which could therefore lead to resistance if MCT1 is simultaneously blocked. To explore this hypothesis, we first examined the effects of both treatments on the different tumor cell lines described in Figure 1 . We confirmed that 3BP was cytotoxic in tumor cell lines expressing MCT1 either as a main path to uptake lactate such as SiHa ( Figure 4A ) and HeLa (not shown) or instead to release lactate such as HL60 ( Figure 4B) and K562 (not shown). In MDA-MB231 cells which express MCT4 but not MCT1 (see Fig.   1A ), 3BP failed to exert cytotoxic effects ( Figure 4C ). Interestingly, we found that the MCT1 
inhibitor AR-C155858 prevented 3BP cytotoxicity in leukemia cells and in cervix cancer cells whereas 7ACC compounds did not ( Figures 4A and 4B) . We next examined whether these observations could also be recapitulated in vivo. We therefore treated SiHa tumor-bearing mice either with 3BP alone or together with AR-C155858 or 7ACC2 compound. We found that ARC155858 abrogated the antitumor effects of 3BP ( Figure 4D ) contrary to 7ACC2 compound ( Figure 4E ). Of note, 3BP as monotherapy was particularly efficient to block SiHa tumor growth (see Figures 4D and 4E) . Based on the observations reported in Figure 3 , we also examined whether the combination of 7ACC and 3BP could influence tumor relapse after the end of treatment. We found that when tumors were collected 15 days after the last drug injection, the tumor volumes of mice exposed to both treatments were systematically smaller than those of mice treated with either single compound ( Figure 4F ). 
DISCUSSION.
The major findings of this study are (i) the identification of compounds endowed with the capacity to block lactate influx but not lactate efflux, and (ii) the demonstration of their in vivo antitumor effects as monotherapy and when combined with another therapeutic modality.
We proved the selective effects of the 7ACC compounds on lactate influx using oxidative cancer cells known to maintain in vitro their capacity to take up lactate as an energetic fuel, and the lack of effects on lactate efflux using highly glycolytic cells. Accordingly, in oxidative human cancer cervix cells, SiHa and Hela, which express both MCT1 and MCT4 isforms, a potent inhibition of both lactate influx and cell proliferation was obtained with 7ACC whereas the bona fide MCT1/MCT2 inhibitor AR-C155858 failed to do so. The effects of 7ACC were confirmed in MCT1/4-expressing pharynx squamous FaDu tumor cells. These observations strongly suggest that 7ACC compounds are inhibitors of lactate entry through both MCT1 and MCT4 preventing any compensatory effects when MCT1, the main path for lactate uptake, is inhibited. Conversely, the 7ACC compounds failed to block lactate efflux from leukemia cells HL60 and K562 (which exclusively express MCT1) whereas the AR-C155858 compound prevented lactate release by 50%. The AR-C155858 compound however failed to block lactate efflux from human breast cancer cell MDA-MB231 which express MCT4 (and possibly MCT2) but not MCT1, underlying the limitation of MCT isoform-specific inhibitory compounds (see below). The distinct behaviours of 7ACC vs AR-C155858 are summarized in is not. Although the demonstration of a similar allosteric modulation of MCT by 7ACC compounds still needs to be done, the profile of such compounds opens new perspectives. First, the lack of activity on lactate efflux is the promise of an absence or at least an attenuation of side effects in all the tissues where lactate release is necessary, including fast-twitch muscle fibers and brain (23, 24) . Activated lymphocytes are also reported to be highly glycolytic and therefore dependent on efficient lactate efflux. The inhibition of lymphocyte proliferation was actually at the origin of the discovery of the AR-C155858 compound family (45) .
Immunosuppressive effects that may be deleterious in the context of cancer patients would therefore be avoided with 7ACC compounds. Second, the capacity to target lactate influx independently of the type of MCT transporter expressed (at least MCT1 and MCT4 in this study) should greatly limit the risk of compensatory mechanism as observed with specific inhibitors such as the AR-C155858 compound. Since most cancers do express these two transporters (25, 46) interference with oxidative healthy tissues that uptake monocarboxylates warrants further investigation; for instance, the impact of 7ACC compounds on either lactate uptake by slowtwitch muscle fibers and neurons, or butyrate capture by the colon should be evaluated in longterm studies.
We next found that 7ACC compounds reduced the extent of SiHa tumor relapse after cisplatin and 3-bromopyruvate treatments. Interestingly, during the course of treatment, tumor growth was inhibited to the same extent by 7ACC administration alone or in combination with either cisplatin or 3BP. Possible reasons for the post-treatment 7ACC-mediated reduction in tumor relapse are numerous and warrant further investigation. Cisplatin administration for instance is known to give rise to resistance phenomena in different cancers, in particular through exacerbation of tumor hypoxia. Interestingly, we previously reported a reduction in the hypoxic fraction of tumors treated with CHC, an unspecific MCT inhibitor, or following genetic silencing of MCT1 expression (11, 12) . Also, we have recently reported that MCT inhibition could lead to anti-angiogenic effects which may contribute to tumor vessel normalization and consecutive restoration of a more homogenous pO 2 through the entire tumor (15) (16) (17) . Labelling of SiHa tumor sections with the hypoxia probe pimonidazole confirmed a net reduction in tumor hypoxia following 7ACC2 treatment (Supplementary Figure 3) .
Although similar mechanisms could account for the better therapeutic outcomes resulting from the combination 3BP/7ACC on tumor relapse, the observed additive effects of the two drugs is paradoxical considering that 3BP enters tumors cells through MCT1 (40) . This means that 7ACC2 compound inhibits lactate entry through MCT but at the same dosage does not interfere with 3BP influx. This observation suggests that 7ACC compounds are lactate-mimetic structures, directly competing with lactate but also with 3-bromopyruvate, another metabolitemimetic exhibiting a monocarboxylate function (see Suppl. Figures 4A and 4B ). It is therefore very likely that the mass action law governs the competitive interaction of 7ACC and 3BP with the transporter in such a way that 3BP preferentially enters cells when its concentration is higher (e.g. 100 µM 3BP vs. 10 µM 7ACC in Figures 4A, 4B and 4C ). Of note, the mode of action of AR-C155858 is very different since this compound family is proposed to bind the intracellular region of MCT1 (36) and to act as a non-competitive inhibitor of lactate. As a result, AR-C155858 can prevent the entry of 3BP and thereby rescue tumor cells exposed to 3BP. Altogether, these data identify an additional advantage of 7ACC compounds since 3BP and 7ACC represent very complementary drugs. By inhibiting lactate influx, 7ACC compounds may indeed prevent tumor cells to use lactate as an energetic fuel, and 3BP by blocking glycolysis reduces the use of glucose to fuel alternate routes to support ATP and biosynthetic intermediates production.
In conclusion, we have identified a new family of compounds that selectively affect a single part of the MCT symporter translocation cycle, leading to inhibition of lactate influx but not lactate efflux. In mice bearing tumors, these compounds exert potent anticancer effects and may also significantly delay tumor relapse following conventional chemotherapy. Importantly, the unique pharmacological profile of 7ACC compounds accounts for critical advantages including a potential reduction in side effects (vs. drugs also interfering with lactate efflux), a lack of resistance due to compensatory mechanisms (vs. drug interfering with MCT1 but not MCT4, or inversely) and a lack of major interference with monocarboxylate-mimectic drugs such as 3BP. 
